Quick Overview: Panelists Richard S. Finn, MD; Richard H. Marshall, MD; and Jordi Bruix, MD; review recent clinical evidence with Panelists Richard S. Finn, MD, and Arndt Vogel, MD, PhD, discuss the management of side effects with sorafenib in hepatocellular ... Madappa Kundranda, MD, PhD, a medical oncologist at Banner MD Anderson Cancer Center, discusses the

Frontline Sirt Vs Systemic Therapy - Detailed Overview & Context

Panelists Richard S. Finn, MD; Richard H. Marshall, MD; and Jordi Bruix, MD; review recent clinical evidence with Panelists Richard S. Finn, MD, and Arndt Vogel, MD, PhD, discuss the management of side effects with sorafenib in hepatocellular ... Madappa Kundranda, MD, PhD, a medical oncologist at Banner MD Anderson Cancer Center, discusses the Further considerations for selecting lenvatinib, sorafenib, Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the importance ... Michael A. Morse, MD, FACP, discusses how the specific goals of a patient are factors in determining the appropriate

Richard S. Finn, MD, discusses his personal experience with regorafenib and nivolumab for his patients with hepatocellular ... Panelists Richard S. Finn, MD; Arndt Vogel, MD, PhD; and Jordi Bruix, MD, provide insight on the recent noninferiority clinical trial ... Criticisms of the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomized studies, which evaluated the efficacy of combining ... Benjamin P. Levy, MD, explains the factors to consider when deciding on a Panelists Richard S. Finn, MD; Richard H. Marshall, MD; Amit Singal, MD, MSCS; and Arndt Vogel, MD, PhD, highlight key factors ... Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of locoregional ...

A review of factors determining eligibility for resection Dr. David Hsieh specializes in hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancers. His research also ... Oliver Waidmann, MD, and Arndt Vogel, MD, discuss how the Tannaz Armaghany, MD, an assistant professor, Internal Medicine, Hematology and Medical Oncology, at Baylor College of ...

Photo Gallery

Frontline SIRT vs Systemic Therapy in HCC
Frontline Treatment in HCC: Systemic vs Locoregional Therapy
HCC: Managing Patients on Frontline Systemic Therapy
Evaluating Systemic Therapies Available for Frontline Treatment of HCC
Frontline Therapy for HCC: Optimizing Treatment Selection
Dr. Kennedy on Importance of SIRFLOX Study in Liver-Metastatic CRC
How Goals Help to Determine Frontline Treatment in HCC
Real-World Evidence and Emerging Frontline Therapies for Advanced Hepatocellular Carcinoma
SIRT Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB Study)
Managing Systemic Treatment in Liver Cancer
Frontline Lenvatinib vs Sorafenib in HCC
Clinical Review of SIRT and Chemo in First-Line mCRC
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored